Establishment Labs Announces Jeffrey Bettinger Has Joined the Company as Global Head of People

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Jeffrey Bettinger as Global Head of People. Bettinger, previously Chief People and Places Officer at Nu Skin, joins the executive team with a focus on culture and human capital strategy. CEO Juan José Chacón-Quirós emphasized the importance of people and culture for the company's upcoming growth and global expansion. Measuring past success in leadership development, Bettinger aims to innovate within the Femtech industry to positively impact women's lives. Establishment Labs specializes in breast aesthetics and has delivered over 1.8 million Motiva Implants in 80+ countries.

Positive

• Appointment of Jeffrey Bettinger as Global Head of People may enhance company culture and employee engagement.
• Mr. Bettinger's extensive experience in leadership roles across various industries can bring valuable insights.
• Focus on expansion into new markets aligns with the company's growth strategy.

Negative

• None.

SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeffrey Bettinger has been appointed Global Head of People.

Mr. Bettinger will join the executive team at Establishment Labs with responsibility for culture, employee experience, and human capital strategy. Mr. Bettinger joins Establishment Labs from Nu Skin, a global leader in beauty and wellness, where he served as the Chief People and Places Officer. He has also held a variety of executive and senior leadership roles in medical devices, financial services, pharmaceuticals, and engineering. His past employers have included USAA, Petco, State Farm, Fluor, and Walmart.

“As we prepare for the significant growth ahead, our people and our culture remain our most valuable assets,” said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. “Jeff will be a powerful voice as we continue to grow globally and ready the Establishment Labs team for our expansion into new markets and for the shifts to come in how we communicate and engage with our consumers.”

Mr. Bettinger has received regional and national recognition for leadership development and culture transformation. He has also published on a variety of human capital topics. Mr. Bettinger earned a bachelor’s degree in communication and a master’s degree in organizational communication and educational administration from Idaho State University. He also holds a Master of Business Administration from Liberty University.

Commenting on his new role, Mr. Bettinger added, “Joining a company in Femtech with such an incredible mission was an immediate draw for me. I am honored to join Juan José and the entire ESTA team as we bring innovation to an industry that has been starved of it for years and in doing so, change the lives of women worldwide.”

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants^® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, more than 1.8 million Motiva Implants^® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora^® tissue expander and Motiva MIA^®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant^® and began a clinical trial to support regulatory approval in the United States. Motiva Implants^® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “intends to,” “would,” “will,” “may” or other similar expressions in this press release. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors that could cause or contribute to these differences include, among others, those risks and uncertainties discussed in the company’s annual report on Form 10-K filed on March 15, 2021, quarterly reports on Form 10-Q, and other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211105005217/en/

Investor/Media Contact:

Raj Denhoy

415 828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

Who is the new Global Head of People at Establishment Labs (NASDAQ: ESTA)?

Jeffrey Bettinger has been appointed as the new Global Head of People at Establishment Labs.

What is Jeffrey Bettinger's experience before joining Establishment Labs (NASDAQ: ESTA)?

Before Establishment Labs, Bettinger served as Chief People and Places Officer at Nu Skin and held leadership roles in various industries.

What is the focus of Establishment Labs (NASDAQ: ESTA)?

Establishment Labs focuses on improving women's health and wellness, primarily in breast aesthetics and reconstruction.

How many Motiva Implants has Establishment Labs (NASDAQ: ESTA) delivered?

Establishment Labs has delivered over 1.8 million Motiva Implants to plastic surgeons in more than 80 countries.

When was the press release regarding Jeffrey Bettinger's appointment at Establishment Labs (NASDAQ: ESTA) issued?

The press release was issued today.